Clinical Trial Detail

NCT ID NCT02591615
Title Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Alliance Foundation Trials, LLC.
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab

Carboplatin + Paclitaxel

Carboplatin + Pemetrexed Disodium

Age Groups: adult

No variant requirements are available.